Drug Trial Radar · NCT02509494
Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo
Last checked: Nov 19, 2026Latest source record: Jul 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,023
Actual
Start
Sep 30, 2015
Primary completion
Jun 28, 2019
Study completion Jul 3, 2019
Sponsor
- Lead sponsor
- Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- London School of Hygiene and Tropical Medicine; Ministry of Health and Sanitation, Sierra Leone; University of Sierra Leone; University of Oxford; Institut National de la Santé Et de la Recherche Médicale, France; Grameen Foundation; World Vision, Ireland
- First posted
- Jul 28, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is the evaluation of the safety and immunogenicity of two candidate Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo, in a 2-dose heterologous regimen.
Conditions
- Ebola Virus Disease
Interventions
Ad26.ZEBOVBiological
Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles.
MVA-BN-FiloBiological
MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit (Inf. U.).
MenACWYBiological
MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
PlaceboBiological
0.9% saline for injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stages 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs) (Day 8)Time frame: 7 days post dose 1 (Day 8)
- Stages 1 and 2: Number of Participants With Solicited Local AEs (Day 64)Time frame: 7 days post dose 2 (Day 64)
- Stage 1: Number of Participants With Solicited Local AEs (Day 738)Time frame: 7 days post dose 3 (Day 738)
- Stages 1 and 2: Number of Participants With Solicited Systemic AEs (Day 8)Time frame: 7 days post dose 1 (Day 8)
- Stages 1 and 2: Number of Participants With Solicited Systemic AEs (Day 64)Time frame: 7 days post dose 2 (Day 64)
- Stage 1: Number of Participants With Solicited Systemic AEs (Day 738)Time frame: 7 days post dose 3 (Up to Day 738)
- Stages 1: Number of Participants With Serious Adverse Events (SAEs)Time frame: Up to 36 months
- Stages 2: Number of Participants With SAEsTime frame: Up to 24 months
- Stage 1: Number of Participants With Unsolicited AEs (Day 759)Time frame: 28 days post booster dose (Day 759)
- Stage 1: Number of Participants With Unsolicited AEs (Day 29)Time frame: 28 days post dose 1 (Day 29)
- Stage 2: Number of Participants With Unsolicited AEs (Day 29)Time frame: 28 days post dose 1 (Day 29)
- Stage 1: Number of Participants With Unsolicited AEs (Day 85)Time frame: 28 days post dose 2 (Day 85)
- Stage 2: Number of Participants With Unsolicited AEs (Day 85)Time frame: 28 days post dose 2 (Day 85)
- Stage 1: Number of Participants With DeathsTime frame: Up to 36 months
- Stage 2: Number of Participants With Deaths (Children and Adolescents)Time frame: Up to 12 months
- Stage 2: Number of Participants With Deaths (Adults)Time frame: Up to 24 months
- Stage 1: Number of Participants With Immediate Reportable Event (IREs)Time frame: Up to 36 months
- Stage 2: Number of Participants With IREs (Children and Adolescents)Time frame: Up to 12 months
- Stage 2: Number of Participants With IREs (Adults)Time frame: Up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Freetown, Sierra Leone
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.